<DOC>
	<DOCNO>NCT00506155</DOCNO>
	<brief_summary>The goal clinical research study learn well bladder cancer respond combination treatment Avastin M-VAC ( methotrexate , doxorubicin , vinblastine , cisplatin ) surgery remove tumor . Primary Objective : To estimate response patient locally advanced urothelial cancer treat neoadjuvant chemotherapy combination Dose Dense Methotrexate , Vinblastine , Adriamycin , Cisplatin ( DD-M-VAC ) plus Avastin follow radical surgery curative intent . In context , response define absence residual muscle invasive cancer resect specimen ( &lt; = pT1 , N0 . ) Secondary Objective : To estimate 4-year disease-free survival patient locally advanced urothelial cancer treat neoadjuvant chemotherapy DD-M-VAC plus Avastin follow radical surgery curative intent . Document perioperative morbidity mortality cohort , reference well-established historical standard . Determine effect VEGF inhibition angiogenesis angiogenesis-related gene expression utilize fluorescent tissue stain technique develop laboratory ( two-color TUNEL , phospho-receptor , microvessel density ) . Interrogate downstream receptor signal pathway provide insight development chemotherapy resistance , hence hypothesis prevention .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Methotrexate , Vinblastine , Adriamycin Cisplatin ( M-VAC ) Plus Avastin Patients With Urothelial Cancer</brief_title>
	<detailed_description>Avastin design prevent slow growth cancer cell block growth blood vessel . Methotrexate , vinblastine , doxorubicin design disrupt growth cancer cell , cause cancer cell start die . Cisplatin atom center contain platinum . The platinum design poison cancer cell , may cause eventually die . If find eligible take part study , treat combination Avastin , methotrexate , vinblastine , doxorubicin , cisplatin . The study drug saline give needle vein . Avastin give 90 minute . Methotrexate give 30 minute . Vinblastine give 30 minute . Doxorubicin give 15 minute . Cisplatin give 4 hour . You also receive saline hydration complete infusion cisplatin . This take 20 hour . If catheter place , chemotherapy drug well saline give catheter . You receive study drug 1 time every 2 week . Every 2 week call study `` cycle '' . On Day 1 cycle , physical exam , include measurement vital sign , height , weight . You ask side effect experience since last visit . Blood ( 2 teaspoon ) urine collect routine test . After 3 cycle therapy , bone scan screen test show sign bone disease . You also repeat cystoscopy . These test do check status disease . You receive total 4 cycle chemotherapy . At least 6 week last dose Avastin , cystectomy ( removal tumor ) . Your doctor explain procedure detail . You sign separate consent form procedure . After surgery , disease lymph nod site , take off-study . After surgery , still disease lymph node site , eligible continue treatment Avastin . Therapy restart sooner 28 day surgery . You receive Avastin every 2 3 week needle vein . Every 2 3 week consider study cycle . Before cycle treatment , blood ( 1 teaspoon ) drawn routine test . Urine collect every cycle routine testing . Every 3 month CT scan MRI check status disease . You may continue receive study drug 18 month therapy . You take study disease get bad intolerable side effect occur . Once off-study , long term follow-up visit every 3-6 month first 30 month every year . These visit continue 4 year , long doctor think necessary . At visit , CT MRI scan abdomen pelvis chest x-ray . Blood ( 1 teaspoon ) draw routine testing . This investigational study . Avastin FDA approve commercially available indication . Its use study consider investigational . Methotrexate , doxorubicin , vinblastine , cisplatin FDA approve commercially available . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Patients must histologic proof urothelial cancer . Patients histologic subtypes eligible long transitional cell carcinoma predominant , 2 exception : More cluster small cell carcinoma treat different chemotherapy ineligible study Patients micropapillary tumor allow irrespective extent transitional cell carcinoma . A transitional cell component require setting pure extensive micropapillary tumor . Note minor histologic component acceptable . 2 . Patients primary tumor arise bladder urethra eligible demonstrate follow feature : A 3dimensional mass examination anesthesia ( EUA ) ; ie : cT3b disease Direct invasion prostatic stroma vaginal wall : ie : cT4a disease Lymphovascular invasion specimen &gt; /= cT1 disease Hydronephrosis present CT scan renal ultrasound Tumor involve bladder diverticulum . 3 . Patients area micropapillary histology eligible , even meet anatomic criterion locally advance disease enumerate . Patients micropapillary histology analyze separate cohort . 4 . Patients primary tumor arise ureter renal pelvis eligible either grade 3 tumor , radiographic abnormality large enough recognize abnormal mass CT MRI image . These patient may also analyze separately , since benchmark data upper tract disease . 5 . Patients must evaluation department urology , deem acceptable surgical candidate . 6 . Patients must adequate physiologic reserve : Zubrod performance status ( PS ) &lt; /= 1 ; 2 recent onset due entirely cancer due comorbidity ( especially compromise performance status relate uncontrolled pain expect rapidly reversible therapy start ) Normal WBC , ANC &gt; /= 1,800 , platelet count &gt; /= 150,000 . Supranormal value judge benign inconsequential etiology acceptable Transaminase ( AST ALT ) &lt; /= 3 * ULN Conjugated bilirubin &lt; /= 1.5 mg/dl ( total bilirubin &lt; /= 2.5 mg/dl ) Normal Serum Creatinine Creatinine clearance ( either measure CockcroftGault formula ) &gt; /= 50 ml/min.CockcroftGault : CLcr = [ ( 140age ) * wt ( kg ) ] / [ 72 * Cr ( mg/dL ) ] ( For female , multiply 0.85 ) 7 . Patients ( Pts ) must NOT clinical evidence disease beyond involve organ either CT MRI abdomen pelvis , chest Xray . Pts lymph node involvement eligible . In absence bone scan , pt free bone pain alk . phos . &lt; 150 % ULN , normal bone fraction alk . phos . If feature present , pts bone scan interpret show evidence metastatic disease eligible . In case bladder tumor , cancer invade local organ ( pT4a ) pelvis sidewall ( pT4b ) allow . 8 . Patients must determination LV function EF &gt; /= 50 % participate . 9 . Women childbearing potential ( i.e. , menses time precede 24 consecutive month ) must negative pregnancy test . Elevations BHCG related tumor ( rapid escalation associate pregnancy , i.e . double time 35 day ) acceptable . 10 . Patients childbearing childfathering potential must agree use acceptable form birth control study , i.e . condom . 11 . Patients second malignancy eligible provide expect outcome second cancer interfere delivery therapy , assessment response cystectomy specimen . The expected survival prior malignancy reliably &gt; 4 year eligible study . 12 . Patients must &gt; /= 18 year age . 1 . Patients must current , recent ( within 3 week ) , plan participation experimental medication clinical trial . 2 . Prior systemic cytoreductive chemotherapy bladder cancer . Please note , prior intravesical therapy allow . 3 . Blood pressure &gt; 140/90 mmHg . Patients whose blood pressure control oral medication eligible , long blood pressure &lt; /= 140/90 mmHg . 4 . Any prior history hypertensive crisis hypertensive encephalopathy . 5 . New York Heart Association ( NYHA ) Grade II great congestive heart failure . 6 . History myocardial infarction unstable angina within 6 month prior study enrollment . 7 . History stroke transient ischemic attack within 6 month prior study enrollment . 8 . Clinically significant peripheral vascular disease ( e.g. , aortic aneurysm , aortic dissection ) . 9 . Symptomatic peripheral vascular disease . 10 . Evidence bleed diathesis coagulopathy . 11 . Known history central nervous system brain metastasis . 12 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study . For purpose study , Cystoscopy ureteroscopy include major surgical procedure . 13 . Lactating woman . 14 . Proteinuria screen demonstrate either : Urine protein : creatinine ( UPC ) ratio &gt; /= 1.0 screening OR Urine dipstick proteinuria &gt; 2+ ( &gt; 100 protein urinalysis ) Patients discover &gt; 2+ proteinuria dipstick urinalysis &gt; 100 urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; = 1g protein 24 hour eligible . 15 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior therapy . Patients Crohn 's disease exclude . 16 . Serious , nonhealing wound , ulcer , bone fracture . 17 . Lung carcinoma squamous cell histology histology close proximity major vessel , cavitation , history hemoptysis ( bright red blood 1/2 teaspoon ; nonsmall cell lung cancer trial ) . 18 . Inability comply study and/or followup procedure , sign inform consent . 19 . Patients candidate surgery , unwilling undergo surgery . 20 . Patients fluid collection ( ascites , pleural effusion ) eligible therapy collection may serve reservoir methotrexate . 21 . Know hypersensitivity component Avastin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Urothelial Cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>M-VAC</keyword>
</DOC>